Drug name - Trulance
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7799897 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun, 2022
(3 months ago) | |
| US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(5 years from now) | |
| US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(11 years from now) | |
| CN103641892B | SALIX | Guanylate Cyclase Receptor Agonist For Treating Tissue Inflammation And Cancer |
Mar, 2022
(6 months ago) | |
| CN102643333B | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis |
Mar, 2022
(6 months ago) | |
| CN102643333A | SALIX | Guanylate Cyclase Receptor Stimulant For Treating Tissue Inflammation And Canceration |
Mar, 2022
(6 months ago) | |
| CN103641892A | SALIX | For Treating Tissue Inflammation And Cancer Of Guanylate Cyclase Receptor Agonist |
Mar, 2022
(6 months ago) | |
| CN105764916B | SALIX | A Hyperpure Agonist Of Guanylate Cyclase C, Preparation And Use Method Of The Agonist |
Jun, 2034
(11 years from now) | |
| CN105764916A | SALIX | A Super-Pure Agonist Of Guanylate Cyclase C, Preparation And Using Method Of The Agonist |
Jun, 2034
(11 years from now) | |
| EP2103624B1 | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis |
Mar, 2022
(6 months ago) | |
| EP2301952A2 | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis |
Mar, 2022
(6 months ago) | |
| EP2944648B1 | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Organ Inflammation |
Mar, 2022
(6 months ago) | |
| EP2301952B1 | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis |
Mar, 2022
(6 months ago) | |
| EP2103624A1 | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis |
Mar, 2022
(6 months ago) | |
| EP2944648A1 | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Organ Inflammation |
Mar, 2022
(6 months ago) | |
| EP2301952A3 | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis |
Mar, 2022
(6 months ago) | |
| EP1379224B1 | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis |
Mar, 2022
(6 months ago) | |
| EP1379224A4 | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis |
Mar, 2022
(6 months ago) | |
| EP1379224A1 | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis |
Mar, 2022
(6 months ago) | |
| EP1379224B2 | SALIX | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis |
Mar, 2022
(6 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
| US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
| US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
| US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(9 years from now) | |
| US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(11 years from now) | |
Drugs and Companies using PLECANATIDE ingredient
Treatment: Irritable bowel syndrome with constipation; chronic idiopathic constipation; Chronic idiopathic constipation; irritable bowel syndrome with constipation
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 3MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.